Skip to content
Open access

A novel synergistic phycobiliprotein combination against HIV-1 shows potent antiviral activity

Aug 2026 · AMB Express · Vol 16 · 0 citations · 72 references
Medicine

TL;DR

The findings highlight the potential of phycobiliprotein-based synergistic formulations as promising candidates for the development of safe and effective anti-HIV-1 therapeutics.

Abstract

Human immunodeficiency virus type 1 (HIV-1) remains a major global public health challenge due to lifelong persistence, latency, and the emergence of drug resistance. Natural bioactive compounds are increasingly being explored as alternative or adjunct antiviral strategies. In this study, we evaluated the antiviral efficacy and cytotoxicity of a synergistic pharmaceutical composition comprising three phycobiliproteins: C-phycocyanin (C-PC), B-phycoerythrin (B-PE), and allophycocyanin (APC), derived from cyanobacteria and marine algae. Individual and combinatorial effects were assessed against HIV-1 using TZM-bl cells and peripheral blood mononuclear cells (PBMCs). A Box–Behnken experimental design was employed to identify optimal synergistic ratios. Among fifteen combinations initially screened at a fixed concentration of 50 µg/mL, five exhibited strong antiviral activity. The optimized formulation (CBA: C2; 73.28% C-PC, 20.70% B-PE, and 6.02% APC) produced up to ~ 100% inhibition of HIV-1 during the screening assay. Subsequent dose-response analyses demonstrated IC50 values ranging from 5.01 to 12.60 µg/mL across different antiviral assays, while exhibiting minimal cytotoxicity (CC50: 577.56 ± 34.5 µg/mL in TZM-bl cells and 247.64 ± 25.49 µg/mL in PBMCs). The formulation showed a high selectivity index, indicating a favourable therapeutic window. These findings highlight the potential of phycobiliprotein-based synergistic formulations as promising candidates for the development of safe and effective anti-HIV-1 therapeutics.

Read PDF

Similar papers

Open access Aug 2026

Combination of Melittin and Clinacanthus nutans Extract Enhances Antiviral Efficacy Against Dengue Virus Serotype 2 Infection

Dengue virus (DENV) remains a major global health threat, particularly in tropical and subtropical regions, due to the lack of effective antiviral therapies. In this study, we evaluated a novel combination strategy using melittin, a bee venom-derived antiviral peptide, together with Clinacanthus nutans extract to enhan...

Natthanich Boonsatit, Somluethai Fungfueang, Saruda Thongyim et al. · 0 citations
Open access Sep 2026

Synthesis and In Vitro Biological Evaluation of Amphiphilic Derivatives of Carvacrol as Potent Antibacterial Agents

The newly developed carvacrol–DABCO amphiphilic hybrids represent a promising class of multitarget antibacterial agents and their broad-spectrum efficacy, bactericidal kinetics, RNA-cleaving activity, low hemolytic toxicity, and favorable selectivity indices support their potential for further in vivo evaluation.

D. Zadvornykh, Mei-Ling Wang, A. Bardasheva et al. · 0 citations
Open access Sep 2026

Antiviral Sesquiterpene Lactones from Laurus nobilis L.: Inhibition of Hepatitis C Virus and Dengue Virus Replication

Natural products remain indispensable scaffolds in antiviral drug discovery, particularly against high-burden viral pathogens. In this study, two major sesquiterpene lactones, dehydrocostus lactone (1) and costunolide (2), were isolated from Laurus nobilis L. leaves and evaluated for their antiviral potential against h...

Yhiya M. Amen, Marwa Elsbaey, George Mpekoulis et al. · 0 citations
Open access Oct 2026

In Vitro Activity and Synergism of Amphotericin B and the Synthetic Bioinspired Peptide γ31-45PvD1++ Against Fungal Study Models Candida tropicalis and Saccharomyces cerevisiae

In recent years, following the COVID-19 pandemic, the emergence of antibiotic-resistant microorganisms has increased. This surge has prompted global research into new biologically active molecules, particularly those focused on combination therapies involving antifungal agents. Synthetic antimicrobial peptides have eme...

T. A. M. Souza, Érica de O. Mello, F. Trindade et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.